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The FSHD2 Gene SMCHD1 Is a Modifier
of Disease Severity in Families Affected by FSHD1
Sabrina Sacconi,1,2,* Richard J.L.F. Lemmers,3 Judit Balog,3 Patrick J. van der Vliet,3 Pauline Lahaut,1
Merlijn P. van Nieuwenhuizen,4 Kirsten R. Straasheijm,3 Rashmie D. Debipersad,3
Marianne Vos-Versteeg,4 Leonardo Salviati,5,6 Alberto Casarin,5,6 Elena Pegoraro,7 Rabi Tawil,8
Egbert Bakker,4 Stephen J. Tapscott,9 Claude Desnuelle,1,2,10 and Silve`re M. van der Maarel3,10
Facioscapulohumeralmuscular dystrophy type 1 (FSHD1) is caused by contraction of the D4Z4 repeat array on chromosome 4 to a size of
1–10 units. The residual number of D4Z4 units inversely correlates with clinical severity, but significant clinical variability exists. Each
unit contains a copy of the DUX4 retrogene. Repeat contractions are associated with changes in D4Z4 chromatin structure that increase
the likelihood of DUX4 expression in skeletal muscle, but only when the repeat resides in a genetic background that contains a DUX4
polyadenylation signal. Mutations in the structural maintenance of chromosomes flexible hinge domain containing 1 (SMCHD1) gene,
encoding a chromatin modifier of D4Z4, also result in the increased likelihood of DUX4 expression in individuals with a rare form of
FSHD (FSHD2). Because SMCHD1 directly binds to D4Z4 and suppresses somatic expression of DUX4, we hypothesized that SMCHD1
may act as a genetic modifier in FSHD1.We describe three unrelated individuals with FSHD1 presenting an unusual high clinical severity
based on their upper-sized FSHD1 repeat array of nine units. Each of these individuals also carries a mutation in the SMCHD1 gene.
Familial carriers of the FSHD1 allele without the SMCHD1 mutation were only mildly affected, suggesting a modifier effect of the
SMCHD1mutation. Knocking down SMCHD1 in FSHD1myotubes increased DUX4 expression, lendingmolecular support to a modifier
role for SMCHD1 in FSHD1. We conclude that FSHD1 and FSHD2 share a common pathophysiological pathway in which the FSHD2
gene can act as modifier for disease severity in families affected by FSHD1.Facioscapulohumeral muscular dystrophy (FSHD [MIM
158900]) is one of the three most common muscular dys-
trophies in adults with an estimated prevalence of
1:20,000.1 Individuals with FSHD have facial, shoulder
girdle, and upper extremity weakness that can spread
with progression of the disease to abdominal, humeral,
anterior lower leg muscles, and (in more severely affected
individuals) to pelvic girdle muscles. The peculiar involve-
ment of specific muscles is such a striking feature that it
often distinguishes FSHD from other forms of muscular
dystrophy.2 The disease usually becomes manifest in the
second decade, but the progression and severity are highly
variable with one-fifth of affected individuals becoming
wheelchair dependent while an equal proportion of gene
carriers remain asymptomatic throughout their lives.3
Autosomal-dominant FSHD1 represents the most com-
mon form, accounting for at least 95% of cases.4 It is
caused by a contraction of the D4Z4 macrosatellite repeat
array located in the subtelomeric region of chromosome
4q. The D4Z4 repeat is highly polymorphic in size, varying
between 11 and 150 units in the general population, each
unit being 3.3 kb in size.5–7 Individuals with FSHD1 have
at least one allele of 1–10 units on chromosome 4.7,8
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between the residual size of the D4Z4 repeat, the age at
onset, and the severity of muscular involvement. Indeed,
small repeat arrays of 1–3 units tend to be associated
with earlier onset and more rapid disease progression.9–12
Gender differences may also account for variability in clin-
ical severity with males being more severely affected then
females.1,13 The marked intrafamilial clinical variability
further suggests the involvement of other genetic or envi-
ronmental factors that modify the disease severity of a
commonly inherited contraction size.
A minimum of one D4Z4 repeat is required to develop
FSHD, suggesting that the repeat itself plays a critical role
in the development of the disease.14 Indeed, each unit
contains a copy of the DUX4 retrogene (MIM 606009)
that becomes inappropriately derepressed in skeletal
muscle of individuals with FSHD.15–18 DUX4 is a germline
transcription factor that is normally repressed in somatic
cells most probably by a mechanism of repeat-mediated
heterochromatin formation. Its expression in skeletal
muscle triggers germline and early stem cell programs,
eventually causing muscle cell death.16,19–21 Consequent
to the contraction, the repressive chromatin structure is
compromised as evidenced by a loss of CpG methylation
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Table 1. Clinical and Biometric Data of the Three Families
Rf Nr Sex AAE
Age at
Onset CSS
MMT
Score Diagnosis
Rf1021 I-1 M 71 unknowna 3 261/300 FSHD1
I-2 F 67 unknowna 4 255/300 FSHD2
II-1 M 48 12 10 65/300 FSHD1þFSHD2
II-2 F 38 – 0 300/300 unaffected
III-1 F 15 – 0 300/300 unaffected
III-2 M 6 5 6 198/300 FSHD1þFSHD2
Rf1110 I-1 M 55 6 10 55/300 FSHD1þFSHD2
I-2 F 53 – 0 300/300 unaffected
II-1 F 26 24 5 280/300 FSHD2
II-2 M 21 unknowna 2 269/300 FSHD1
Rf1121 II-1 M 67 15 10 75/300 FSHD1þFSHD2
Abbreviations are as follows: CSS, clinical severity score; AAE, age at the last ex-
amination; MMT, manual muscle testing.
aThese patients do not report any symptoms.and modifications22–24 and the concomitant gain in tran-
scription-activating chromatin marks.25 Together, these
changes in D4Z4 chromatin increase the likelihood of
DUX4 expression in skeletal muscle, leading to a varie-
gated pattern of DUX4-positive myonuclei.17,18,26
For FSHD to result, D4Z4 contraction needs to occur on
FSHD-permissive chromosomal backgrounds.27,28 Internal
copies of the DUX4 retrogene do not have a polyadenyla-
tion signal (PAS) but the distal copy of the D4Z4 repeat
array can make use of a polymorphic PAS present on
approximately one-half of the chromosome 4, commonly
referred to as 4qA chromosomes (e.g., 4A161).15,29,30 In the
absence of this DUX4 PAS, such as on 4qB chromosomes
and on chromosome 10where a highly homologous repeat
array resides, transcriptional derepression of the FSHD
locus does not normally lead to the production of stable
DUX4 transcripts or to the appearance of FSHD clinical
phenotype.29,31
A small group of individuals with FSHD show D4Z4
chromatin changes and DUX4 derepression in skeletal
muscle in the absence of repeat array contraction. These
individuals with FSHD2 (MIM 158901) carry at least one
FSHD-permissive 4qA allele and are clinically identical to
individuals with FSHD1.22,23,32 Unlike families with
FSHD1 where the chromatin changes are mostly occurring
on the contracted allele, in families with FSHD2, D4Z4
chromatin relaxation occurs on the D4Z4 repeat arrays of
both chromosomes 4 and 10. Recently we showed that
in the majority of families with FSHD2, the disease is
caused by digenic inheritance of a DUX4 PAS-containing
chromosome 4 and a mutation in the structural mainte-
nance of chromosomes flexible hinge domain containing
1 (SMCHD1 [MIM 614982]) gene on chromosome 18.33
SMCHD1 is a chromatin modifier necessary for the estab-
lishment and maintenance of CpG methylation of theThe Americinactive X chromosome and specific classes of repeated
elements.34–36 FSHD2 individuals have reduced SMCHD1
binding to the D4Z4 repeats on all four chromosomes,
suggesting a haploinsufficiency mechanism. In support,
knockdown of SMCHD1 in control myotube cultures
with normal-sized D4Z4 repeat arrays on FSHD-permissive
DUX4-PAS containing chromosomes leads to the transcrip-
tional activation of DUX4.33
Because both FSHD1 and FSHD2 result from the somatic
derepression of DUX4, we investigated whether SMCHD1
may act as a modifier for disease severity in families with
FSHD1 and may have a role in the marked variability of
clinical expression that is encountered in some families.
Previous studies were only partially successful in explain-
ing the variation in clinical severity in individuals with
FSHD1. In addition to the inverse correlation with the
residual repeat size,9,11,12,37 CpG methylation and histone
modification studies of D4Z4 have likewise uncovered only
rough correlations between residual methylation levels
and clinical severity, with the most severely affected indi-
viduals with the smallest repeat sizes showing the largest
reduction in repressive chromatin modifications.38,39
To identify modifiers of disease severity, of particular in-
terest are those families with FSHD1 carrying upper-sized
D4Z4 repeat arrays of 8–10 units, as shown by the fact
that carriers of these alleles are more likely to have a partial
or less severe form of FSHD or to be asymptomatic.40–42
To explore the possibility that mutations in SMCHD1
may modify the disease severity in families affected by
FSHD1, we investigated the SMCHD1 locus in six unrelated
individuals with FSHD1 from a cohort of 53 independent
families with FSHD1 which carried a FSHD allele of 8–10
D4Z4 units. These individuals were selected based on
D4Z4 methylation levels <25% indicative for FSHD2.33
We report that three of them have a mutation in SMCHD1
although in the remaining cases the cause for D4Z4 hypo-
methylation remains to be identified. These three cases
have a repeat array of nine D4Z4 units on a FSHD-permis-
sive DUX4 PAS-containing chromosome and show an
unusually severe clinical presentation of the disease based
on clinical evaluation that includedmanual muscle testing
of 60 muscles and determination of the clinical severity
score.39 The relevant biometric and genetic observations
in these families are summarized in Table 1 and Table S1
available online. Pedigrees and genetic analyses of these
three families are presented in Figure 1A. Signed and
informed consent was obtained from all participants and
family members according to protocols approved by the
Institutional Ethics Review Boards of the University Hospi-
tal of Nice and collaborating institutes.
In the first family (Rf1021), the proband (II-1) has been
followed in our Center since the age of 35 when he became
wheelchair dependent. He started to experience asym-
metric scapular weakness at the age of 18, but he reported
inability to blow into a flute at the age of 12. During the
last examination, at age 48, he presented with severe and
asymmetric facial weakness of orbicularis oculi and oris,an Journal of Human Genetics 93, 744–751, October 3, 2013 745
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Figure 1. Genetic and Epigenetic Characterization of Three Families Affected by FSHD
(A) Pedigrees of the families with complete genetic data. Top: Pedigrees are shown of all three families, individuals in light gray were not
available. Below each individual, information is given for the methylation level at the FseI site in the first units of the D4Z4 arrays (%)
and the presence (SMC) or absence (CTR) of a SMCHD1mutation. In addition, information is given for the size of the D4Z4 repeat arrays
on chromosome 4 (in units) and the distal variation (A or B). Shaded boxes indicate FSHD-permissive genetic features. For example, in-
dividual I-1 of family Rf1110 has an FseI methylation level of 8% and is carrier of a SMCHD1mutation. He carries one D4Z4 repeat array
of 9 units on a 4A chromosome and one array of 63 units on a 4A chromosome. Middle: Methylation data of all three families with
genomic DNA digested with restriction enzymes EcoRI, BglII, and methylation-sensitive FseI. Methylated (M) and unmethylated
(UM) D4Z4 fragments are indicated. Bottom: D4Z4 repeat sizing data of samples in middle panel by double digestion of genomic
DNA with EcoRI and HindIII (E) or with EcoRI and BlnI (B), followed by hybridization with probe p13E-11. Chromosome 4-derived
D4Z4 arrays are BlnI resistant whereas chromosome 10-derived arrays are not. The disease-associated 9 units arrays (35 kb) are indicated
with an asterisk. The cross-hybridizing DNA fragment on the Y chromosome is labeled with Y. Marker lanes are indicated on the right
and left of the gel. Individual I-II of family Rf1110 was run on a separate gel as indicated with the vertical hairline.
(B) Sequence traces of the SMCHD1mutations in all three families and in control samples. Exonic sequences are indicated in black and
intronic sequences in white. The position of the heterozygous mutations are indicated above the sequence traces and are highlighted in
yellow. The genomic position is based on UCSC Genome Browser hg19 chromosome 18, the transcript position on RefSeq accession
number NM015295, and the protein position on NP056110.
(C) Overview of RNA analysis. Left: RT-PCR analysis via primers flanking the identified mutation on cDNA prepared from total RNA iso-
lated from blood. The agarose gel images show RT-PCR fragments from the FSHD2 individuals (þ). In addition, water control () and
marker (M) lane are indicated. Right: RT-PCR sequence traces of the region covering the mutation in all three families. For the missense
mutation in Rf1021, the evolutionary conservation is shown. For Rf1110, sequence traces are shown from wild-type (WT) and mutant
allele (mt), the latter showing a skip of exon 24. In Rf1121 the 1 bp deletion indicated by the arrow causes mixed sequence traces.marked shoulder girdle weakness associated with bilateral
scapular winging, and humeral weakness. He displays
marked hyperlordosis resulting from abdominal muscle746 The American Journal of Human Genetics 93, 744–751, Octoberweakness and weakness and atrophy of lower legs. Distal
upper limb muscles are also becoming involved. He has a
clinical severity score (CSS) of 10.113, 2013
Genetic analysis showed that this proband carries a nine
D4Z4 unit 4A161 allele, confirming the diagnosis of
FSHD1. His 6-year-old son (III-2) was referred to our Center
because of difficulties in raising his arms and a history of
frequent falls. At examination he presented with weakness
of the orbicularis oculi muscles, mild shoulder girdle weak-
ness with scapular winging, Gower’s sign, and asymmetric
foot dorsiflexor weakness (CSS 6).
We also examined the proband’s daughter (III-1), 15
years old, and concluded that she was clinically unaf-
fected. The father of the proband (I-1), at age 71, displayed
mild facial and asymmetric shoulder girdle weakness
(CSS 3) and the mother of the proband (I-2: 67 years old)
showed asymmetric facial weakness and shoulder girdle
involvement (CSS 4). Neither of them was complaining
of any symptom except for arm fatigability. Extensive ge-
notype, methylation, and SMCHD1 mutation analysis in
this family showed that the proband’s father is a mildly
affected individual with FSHD1 carrying the nine D4Z4
units on a 4A161 allele without a mutation in SMCHD1,
consistent with the intermediate D4Z4 methylation levels.
The proband’s mother, also mildly affected, is an individ-
ual with FSHD2 carrying a normal-sized 4A161 allele and
a mutation in the SMCHD1 gene (c.1580C>T, Figure 1B).
This mutation has not been reported previously in dbSNP,
the 1000 Genomes Project, the ESP Exome Variant Server,
or in-house databases and predicts a change of the amino
acid threonine to methionine at protein position 527.
The mutation was classified as damaging by the prediction
programs PolyPhen-2, PMUT, and SNAP and confirmed in
the RNA of the proband (Figure 1C). The proband and his
affected son have inherited alleles for both FSHD1 (nine
units 4A161 allele) and FSHD2 (marked hypomethylation
of D4Z4 loci associated with c.1580C>T mutation in
SMCHD1), suggesting a possible explanation for the
severity of clinical phenotype in the proband and the un-
usual early onset in the son.
In the second family (Rf1110), the proband (I-1) was
examined in our Center at the age of 56 showing, since
the age of 6, a progressive and asymmetric weakness of
facial muscles, shoulder girdle muscle weakness associated
with scapular winging, and humeral muscle weakness.
Abdominal weakness was also observed with marked
hyperlordosis and pelvic girdle muscle weakness. Upon
examination, the lower leg muscles were also affected
(CSS 10). This person became wheelchair dependent by
the age of 39. The diagnosis of FSHD1 was confirmed by
the presence of a D4Z4 repeat array of nine units on a
4A161 allele.
His mother and father have no history of muscle disease
and have not been examined. His son (II-2), 21 years
old, was diagnosed as an asymptomatic FSHD1 carrier
because he inherited the contracted 4A161 allele. At
examination he showed very mild facial weakness and
shoulder girdle involvement with mild right scapular
winging (CSS 2). The daughter (II-1), 26 years old, did
not inherit the contracted D4Z4 repeat array of nine unitsThe Americand was considered unaffected. On clinical examination,
however, she had mild asymmetric facial weakness,
scapular winging, and right anterior leg weakness. Func-
tionally, this person’s only complaints are fatigability in
right foot dorsiflexion and in arm raising above her
head (CSS 5).
Methylation studies revealed slightly lower D4Z4
methylation levels in II-2, consistent with FSHD1 diag-
nosis and a marked hypomethylation in individuals I-1
and II-1, suggestive of FSHD2. These results prompted us
to perform SMCHD1 mutation analysis resulting in the
identification of a mutation in both individuals in a highly
conserved nucleotide of the 50 splice consensus site of exon
24, which has not been reported in any of the public
databases (Figure 1B). RNA analysis in I-1 showed that
this mutation leads to skipping of exon 24 (Figure 1C).
In summary, in this family, the proband (I-1) carries the
diagnosis of FSHD1 and FSHD2 and has a severe pheno-
type. The proband’s daughter (II-1), diagnosed with
FSHD2, and his son (II-2), diagnosed with FSHD1, are
only mildly affected.
In the last family (Rf1121), only individual II-1 was avail-
able for examination because his mother died at age 28
from delivery complications and his father died at age 35
from a work accident. He has no family history of muscle
disease and no offspring. At age 15 he was noted to have
asymmetric facial weakness of orbicularis oculi and orismus-
cles, shoulder girdle involvement with scapular winging,
and abdominal muscle weakness. Anterior lower leg weak-
ness appeared at the age of 30 and pelvic girdle muscles
were subsequently involved. At the age of 33 he was
walking with a cane. At the age of 40 he becamewheelchair
dependent and was unable to lift his arms. At his most
recent examination (at age 65), his CSS was 10. Extensive
genotyping of D4Z4 repeats on chromosomes 4 and 10
showed nine D4Z4 units on a 4A161 allele, confirming
the diagnosis of FSHD1. Methylation studies revealed pro-
found D4Z4 hypomethylation and SMCHD1 mutation
analysis identified a SNP in exon 38 that is predicted to
result in a frameshift in the SMCHD1 open reading frame,
confirming the additional diagnosis of FSHD2 (Figure 1B).
The frameshift mutation was confirmed in the RNA of in-
dividual II-1 (Figure 1C). In conclusion, these genetic and
clinical data suggest that a mutation in SMCHD1 gene
can act as a modifier of disease severity in individuals
with FSHD1.
Previously, we showed that depletion of SMCHD1 by
RNA interference in control myotubes carrying a normal-
sized D4Z4 repeat leads to the transcriptional activation
of DUX4.33 According to our clinical observations
implying a synergistic effect of a D4Z4 contraction and a
SMCHD1 mutation on transcriptional derepression of
DUX4, we hypothesized that depletion of SMCHD1 in
FSHD1 myotubes may result in transcriptional activation
of DUX4 beyond that observed in FSHD1 myotubes,
potentially resulting in a more severe phenotype. We
tested this hypothesis by lentiviral transduction ofan Journal of Human Genetics 93, 744–751, October 3, 2013 747
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Figure 2. Depletion of SMCHD1 in FSHD1 Myoblast Augments
DUX4 Expression
SMCHD1 depletion in FSHD1 primary myotubes leads to upregu-
lation of DUX4 and DUX4 target transcripts RFLP2B, TRIM43, and
ZSCAN4. Three FSHD1 myoblast cell lines (FSHD1a, FSHD1b, and
FSHD1c) were transduced 48 hr prior to differentiation with lenti-
viral particles harboring scrambled shRNA constructs or SMCHD1
targeting constructs as described previously.33 After myotube for-
mation, cells were harvested for protein and RNA isolation.
cDNA was prepared and mRNA levels were measured by qRT-
PCR as described.33
(A) Immunoblot analysis shows that SMCHD1 protein is depleted
in myotubes transducted with shRNA constructs against SMCHD1
(S) and not with scrambled shRNA (C). Tubulin is used as a loading
control.
(B) Relative expression levels of DUX4 and DUX4 target genes
RFLP2B, TRIM43, and ZSCAN4 in SMCHD1-depleted FSHD1 myo-
tubes. y axis depicts relative changes in expression levels corrected
against housekeeping gene beta-glucuronidase after SMCHD1
depletion normalized to expression levels of samples without
SMCHD1 depletion. Error bars represent standard error of the
mean.SMCHD1 shRNAs into three independent FSHD1myotube
cultures and observed increased levels of DUX4 mRNA in
myotubes with sufficient SMCHD1 knockdown (Figure 2).
Consequent to the increase in DUX4 protein levels, we also
detected transcriptional activation of the known DUX4
target genes ZSCAN4, RFLP2B, and TRIM43. Because two
of the three myotube cultures are heterozygous for an
FSHD-permissive 4qA chromosome with contracted D4Z4
repeat and a nonpermissive 4qB chromosome that cannot
produce DUX4 in somatic cells (see Table S2), the increase
in DUX4 levels upon SMCHD1 knockdown can be ex-
plained only by further chromatin relaxation of the con-
tracted FSHD1 repeat.
The marked variability in clinical severity, age at onset,
and rate of progression, even between close relatives, is a
clinical hallmark of FSHD. This feature, already reported
in the first description of this disease in the late 1800s,43
was confirmed in later studies.1,12 Although residual repeat
size D4Z4 methylation levels account for some of the vari-
ability, other (genetic) modifiers must contribute to the748 The American Journal of Human Genetics 93, 744–751, Octoberdisease presentation, as was also concluded from popula-
tion-based studies.27,44,45
In this context, the identification of three unrelated in-
dividuals with unusually severe clinical phenotypes associ-
ated with a borderline FSHD1 allele, and the presence of
marked intrafamilial variability of disease severity in
some familial carriers of the FSHD1 allele prompted us to
consider the possibility that additional genetic defects
may segregate in these families acting as disease modifiers.
‘‘Double trouble’’ in FSHD has been reported previously in
isolated cases.46–48 In these cases, however, it was the result
of concomitant mutations in other dystrophy genes and
resulted in atypical FSHD phenotypes, suggesting synergis-
tic effects of the two genetic lesions, rather than a genetic
modifier acting on the D4Z4 locus itself. Nevertheless, we
excluded mutations in VCP, FHL1, and CAPN3 by
sequencing and (by histology, immunohistochemistry,
and immunoblot studies on probands’ muscle biopsy)
known muscular dystrophies and myopathies that could
present with a clinical phenotype resembling FSHD49
(data not shown).
Our recent discovery that mutations in SMCHD1 cause
FSHD2, the direct role for SMCHD1 in the chromatin struc-
ture of D4Z4, and the indistinguishable phenotypes be-
tween individuals with FSHD1 and those with FSHD2 led
us to investigate SMCHD1 as a potential genetic modifier
in FSHD1. We proposed that even though FSHD1 and
FSHD2 do not have the same genetic defect, both probably
have a common pathophysiological pathway converging
on transcriptional derepression of DUX4 in skeletal
muscle.50 Our observations in the present study, in addi-
tion to suggesting that SMCHD1 can act as a disease mod-
ifier, further support the hypothesis that FSHD1 and
FSHD2 share a common pathophysiological pathway. Indi-
viduals with combined FSHD1 and FSHD2 genetic defects
have amore severe clinical phenotype than expected based
on the borderline repeat size of the FSHD1 allele, whereas
individuals within the same family with only the FSHD1
borderline allele or the FSHD2 genetic defect were less
severely affected. These findings suggest an additive effect
of the SMCHD1 mutation on the pathophysiological
pathway triggered by D4Z4 repeat array contraction by
creating additional chromatin relaxation above the
levels caused by D4Z4 contraction. This observation may
explain why in occasional FSHD families the disease does
not seem to segregate with a contracted 4qA allele.42,51
Considering the frequency of borderline D4Z4 repeat
arrays in the population, we have to be alert for the possi-
bility of an SMCHD1 mutation, or SMCHD1 variants that
might influence its activity on D4Z4, when counseling
families with FSHD. Based on this study, we would recom-
mend SMCHD1 mutation testing in cases with upper
FSHD-sized repeat arrays (8–10 units) with an unusual
early onset or rapid disease progression. However, further
studies are necessary in a larger cohort of individuals
with FSHD1 in order to assess the effect of SMCHD1 as
disease modifier.3, 2013
In addition to SMCHD1, it is likely that other environ-
mental or (epi)genetic factors are involved in modifying
disease severity by facilitating or inhibiting the clinical
expression. These might be trans-acting factors like other
chromatin modifiers involved in repeat mediated gene
silencing or cis-acting factors such as other SNPs in the
distal end of the repeat that are unique to the FSHD-
permissive alleles and that may affect D4Z4 chromatin
structure by facilitating or inhibiting chromatin factor
binding or processing of the D4Z4 transcripts. There
have been only a few successful attempts at identifying
modifier genes in Mendelian disorders.52 Recently, exome
sequencing in an extreme phenotype study design facili-
tated the identification of variants in DCTN4 predisposing
to specific parameters of P. aeruginosa airway infections in
individuals with cystic fibrosis.53 To identify additional
modifiers in FSHD, it is therefore imperative to study in
detail FSHD-affected individuals with unusual phenotypes
or genotypes as we have done here and to continue to
study the complex regulation of D4Z4 during development
and in different populations.Supplemental Data
Supplemental Data include two tables and can be found with this
article online at http://www.cell.com/AJHG/.Acknowledgments
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